CT/NG Testing Market Projected to Grow at 8.1% CAGR, Surpassing USD 3.2 Billion by 2031.

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global CT/NG Testing Market- (By Product (Assays & kits, Instruments/Analyzers), By Test Type (Laboratory, Point-of-care testing), By Technology (INAAT, PCR, Immunodiagnostics, Others), By End-User (Diagnostics & Laboratories, Hospitals & Clinics, Others)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031."

According to the latest research by InsightAce Analytic, the Global CT/NG Testing Market is valued at US$ 1.65 Bn in 2022, and it is expected to reach US$ 3.27 Bn by 2031, with a CAGR of 8.1% during a forecast period of 2023-2031.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/1984

Chlamydia is a sexually transmitted disease formed by the bacterium Chlamydia Trachomatis. Chlamydia Trachomatis infections in women are frequently asymptomatic, but if ignored, they can cause pelvic inflammatory disease (PID), which can lead to additional issues such as infertility, ectopic pregnancy, and persistent pelvic pain. Gonorrhoea is a sexually transmitted illness (STD) that is caused by the bacteria Neisseria gonorrhoea. Infections with N. gonorrhoea are more prevalent in young adults. Individuals who have several sexual partners, people who have another STD, men who have sex with men (MSM), and sex workers are also at a higher risk of getting gonorrhoea. High STD incidences and rising government backing are driving the CT/NG market expansion.

List of Prominent Players in the CT/NG Testing Market:
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Hologic, Inc. (US),
• Thermo Fisher Scientific Inc. (US),
• Abbott Laboratories (US),
• Bio-Rad Laboratories, Inc. (US),
• Siemens Healthineers AG (Germany),
• Danaher (US),
• Becton,
• Dickinson and Company (US)

Market Dynamics:
Drivers-
Growth prospects in the CTING testing market are provided by government initiatives, schemes, or financing activities that encourage and promote innovation and development. These financial incentives and support systems enable businesses to invest in R&D, infrastructure, and the development of sophisticated diagnostic technologies. Manufacturers are encouraged to push the boundaries of CT/NG testing by facilitating access to financing, leading to breakthrough technologies in disease detection, monitoring, and personalized medicine. For example, during National STD Awareness Week in April 2022, the Chiricahua Community Health Centres, Inc. (CCHCI) announced a collaboration with The Body Agency Collective (TBAC) and Visby Medical, Inc. to improve sexually transmitted infection (STI) diagnosis and treatment.

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2024-02

Challenges:
The variable expenses of the essential reagents, instruments, and those set up by the vendors raise the overall cost. Extra expenditures include maintenance and insurance, laboratory supervision, and administrative costs (including rent, office space, and administration). Only large hospitals and reference laboratories with large capital budgets may be able to afford such a large amount of diagnostic equipment. Small laboratories, medical offices, and private or individual practitioners, on the other hand, may have capital limits and hence find it difficult to acquire large or large apparatus and analyzersanalyzers. CT/NG testing kits and instruments can range in price from USD 2,000 to USD 80,000. These expensive restrictions may stymie the expansion of the CT/NG (STI) testing business.

Regional Trends:
Asia-Pacific had the highest CAGR and is expected to sustain this trend throughout the projected years. This is owing to the rise in the count of cases of sexually transmitted illnesses in developing countries. Furthermore, increased patient awareness through education campaigns and expanding government efforts are expected to propel the CT/NG testing market forward.

Recent Developments:
• In May 2022, - Abbott said that its Alinity m STI Assay had been approved by the FDA. The test finds and separates four common sexually transmitted diseases (STIs) at the same time. If STIs aren't addressed, they can cause serious health problems, like an increased chance of getting certain cancers or being unable to have children.
• In Oct 2022, Bio-Rad released two Exact Diagnostics molecular controls. The CT/NG Positive Run Control was designed for molecular tests of Chlamydia trachomatis and N. gonorrhoeae. The company said the STI Negative Run Control monitored the absence of Chlamydia trachomatis and Neisseria gonorrhoeae in molecular assays and could be used to detect laboratory testing errors, including contamination events while controlling for sample adequacy.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/1984

Segmentation of CT/NG Testing Market-
By Product-
• Assays & kits
• Instruments/Analyzers
By Test Type-
• Laboratory,
• Point-of-care testing
By Technology-
• INAAT,
• PCR,
• Immunodiagnostics
• Others
By End-User-
• Diagnostics & Laboratories
• Hospitals & Clinics
• Others
By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• South East Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of the Middle East and Africa

Empower Your Decision-Making with 180 Pages Full Report @ https://www.insightaceanalytic.com/buy-report/1984

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 551 226 6109
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.